Skip to content

The effect of iron and omega-3 on coronary heart disease

The effect of supplementation with iron alone and combined with the docosahexaenoic acid and changes in serum lipid profile on risk of Coronary- heart disease via measuring paraoxonase 1, hs-CRP and the ApoB / ApoA1 ratio in women with iron deficiency anemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201301182709N27
Enrollment
80
Registered
2013-03-24
Start date
2013-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Iron deficiency anaemia. Condition 2: Iron deficiency anaemia. Iron deficiency anaemia, unspecified Other iron deficiency anaemias

Interventions

Sponsors

Tehran University of Medical Sciences and Health services
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: • Serum ferritin less than 12 ? g / l and serum iron of 60 mcg/100ml • Women in the range of 15 to 45 years of age • regular menstrual cycles • willingness to cooperate and fill the criteria of informed consent form to the project exclusion criteria: • smoking tobacco or alcohol • iron supplements, multivitamins and antioxidants in the last three months • the use of lipid-lowering drugs, oral contraceptives • the use of oral contraceptives • parasitic infections (those who have been diagnosed positive stool test will be excluded.) • thalassemia disease • kidney disease, liver disease, diabetes • local or systemic infection or inflammatory disease • history of ulcer disease or gastrointestinal bleeding or fibroids •malabsorption such as celiac sprue or steatorrhea • Any type of blood transfusion in the last 2 months of • pregnancy or lactation • not wanting to continue working • inadequate compliance supplement (compliance less than 80%) • change in diet or physical activity for any reason

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting serum ferritin. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: According ? g / l Lyazvn method.;Paraoxonase 1 activity. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: By U / L spectrophotometry.;Fasting serum ApoB levels. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: Based on Mg / dl Turbydymtry method.;Fasting serum concentrations of ApoA1. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: Based on Mg / dl Turbydymtry method.;Fasting concentrations of serum HS-CRP. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: Based on Mg / l immunohistochemical method Flumtryk.;Fasting serum iron. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: According ? g / dl spectrophotometry.

Secondary

MeasureTime frame
Potassium. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (mg/day) over a 24-hour dietary questionnaire.;Kind of fat. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (mg/day) over a 24-hour dietary questionnaire.;Level of physical activity. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: In terms of intensity (light, medium and heavy) information through a questionnaire.;Body mass index. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Kg/m2 calculated based on the height and weight.;Age. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: In terms of the question.;Energy intake. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (kcal / day) over a 24-hour dietary questionnaire.;Carbohydrate intake. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (g/day) over a 24-hour dietary questionnaire.;Protein intake. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (g/day) over a 24-hour dietary questionnaire.;Fat intake. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (g/day) over a 24-hour dietary questionnaire.;Fiber intake. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (g/day) over a 24-hour dietary questionnaire.;Vitamin A. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (mg/day) over a 24-hour dietary questionnaire.;Vitamin C. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (mg/day) over a 24-hour dietary questionnaire.;Vitamin E. Timepoint: Before the experiment, 12 weeks after intervention. Method of measurement: Terms (mg/day) over a 24-hour dietary questionnaire.;Betacar

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Amani

Tehran University of Medical Therapy

s.amani5n@gmail.com+1 232370630

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026